{"product_id":"argenx-five-forces-analysis","title":"arGEN-X Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003earGEN‑X operates in a high-stakes biotech niche where supplier complexity, regulatory hurdles, and incumbent rivalry shape strategic outcomes; our snapshot highlights key pressures like concentrated supplier power and evolving substitute therapies. This brief only scratches the surface—unlock the full Porter's Five Forces Analysis to explore force-by-force ratings, visuals, and actionable insights tailored to arGEN‑X’s market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Biologic Manufacturing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of efgartigimod and similar antibody therapies needs high-tech CDMOs (contract development and manufacturing organizations) with cell-line, GMP, and fill-finish capacity; fewer than 100 global sites meet advanced biologics standards in 2025, concentrating power. These suppliers charge premium rates—CDMO biologics slot prices rose ~22% in 2024—while argenx faces huge switching costs: technical transfer, multi-month process validation, and regulatory re‑approval that can cost tens of millions and delay supply by 12–24 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScarcity of Highly Skilled Scientific Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2025 biotech talent war for immunology and clinical development is acute: global demand grew 18% YoY in 2024 and median senior immunologist pay rose to about $250k–$320k in the US, boosting labor costs for argenx. argenx relies on specialized staff to run its SIMPLE Antibody platform and 20+ active trials, so top scientists and consultants command strong leverage on pay, headcount priority, and budget allocation. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Research Tools and Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eargenx depends on proprietary reagents and high-end lab gear from a few suppliers (eg Thermo Fisher, Danaher), which gives suppliers pricing and contract leverage; 2024 market data shows top 5 life‑science suppliers held ~60% share, raising input cost risk for biologics R\u0026amp;D.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpargenx often partners with top academic centers for discovery but those institutions exert supplier power via patents and exclusive rare-disease patient datasets which can limit argenx bargaining room.\u003e\u003cp\u003eIn 2025 argenx reported 2024 R\u0026amp;D spend of €511m and must secure licensing terms that avoid high royalty floors or equity dilution that would erode long-term margins and ROIC.\u003c\/p\u003e\u003cp\u003eNegotiating upfront payments, milestone caps, and data-access clauses is critical to keep pipeline control and predictable cost profiles.\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcademic IP + patient data = high leverage\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D €511m — pressure on margins\u003c\/li\u003e\n\u003cli\u003eUse upfront limits, capped royalties, data rights\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pargenx\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Logistics Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMaintaining cold-chain integrity for argenx’s antibody therapies needs global logistics firms with temperature-controlled networks; in 2024 cold-chain pharma logistics grew 8.5% to a $81.5B market, concentrating capacity among ~10 top providers.\u003c\/p\u003e\n\u003cp\u003eAs argenx expands into EU, US, and APAC, reliance on these specialists rises, giving suppliers leverage to set higher fees and tighter contract terms tied to compliance with GDP and IATA regulations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain market: $81.5B (2024), +8.5% CAGR\u003c\/li\u003e\n\u003cli\u003eTop ~10 firms hold majority capacity\u003c\/li\u003e\n\u003cli\u003eCompliance drivers: GDP, IATA, local regulators\u003c\/li\u003e\n\u003cli\u003eSupplier leverage increases with international launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier squeeze: concentrated CDMOs, rising slots \u0026amp; high switching costs pressure argenx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers (CDMOs, specialist reagents, cold‑chain, academic IP) hold strong leverage over argenx in 2025 due to concentrated capacity (\u0026lt;100 advanced biologics CDMOs), rising slot prices (+22% in 2024), top‑5 reagent vendors ~60% share, cold‑chain market $81.5B (2024), and high switching costs (technical transfer 12–24 months, multi‑$m). Negotiation levers: capped royalties, upfront limits, data rights.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvanced CDMO sites\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO slot price change\u003c\/td\u003e\n\u003ctd\u003e+22% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑5 reagent share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain market\u003c\/td\u003e\n\u003ctd\u003e$81.5B (2024), +8.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eargenx R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€511m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for arGEN‑X that uncovers competitive drivers, buyer and supplier power, entry barriers, substitutes, and disruptive threats to its biologics-focused market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces snapshot tailored for arGEN-X—rapidly assess competitive intensity and strategic levers to reduce pricing and regulatory risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidated Payer and PBM Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConsolidated US insurers and PBMs, which cover ~80% of lives via top 5 PBMs, push steep rebates and strict formulary tiers, cutting argenx’s list-price power for Vyvgart (approved 2021).\u003c\/p\u003e\n\u003cp\u003eThey require head-to-head evidence of superior outcomes and often demand rebates exceeding 30–40% for preferred placement, limiting argenx’s margin despite its FcRn antagonist novelty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Systems and HTA Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Europe and parts of Asia, government HTA (health technology assessment) bodies—like NICE in England and IQWiG in Germany—control reimbursement and often force price caps; in 2024 NICE issued 12 major appraisals affecting biologics pricing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Hospital and Infusion Center Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA large share of argenx’s 2024 product revenue flows through major hospital systems and infusion networks that handle biologics for thousands of patients, letting them demand volume discounts and extended payment terms. These buyers negotiated rebates often exceeding single-digit percentages in oncology\/rare-disease biologics in 2023–24, pressuring gross margins. Their control over physician prescribing and site-of-care shifts gives them high bargaining leverage, affecting launch pricing and reimbursement timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups and Consumer Power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups in rare disease and autoimmune care steer regulator and payer priorities, shaping access for argenx’s therapies—advocacy influenced the 2024 EU and US reimbursement debates for neonatal and orphan indications, raising public and payer scrutiny.\u003c\/p\u003e\n\u003cp\u003eThough not payers, these groups push argenx into costly patient support and copay programs; argenx reported $120–150m annual patient-support expenses in 2024 estimates, cutting net realized price.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy shapes reimbursement decisions\u003c\/li\u003e\n\u003cli\u003eDrives demand, not direct purchases\u003c\/li\u003e\n\u003cli\u003eForces patient-support spending (~$120–150m in 2024)\u003c\/li\u003e\n\u003cli\u003eReduces net realized price and margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Alternative Treatment Protocols\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpphysicians and hospitals can switch between argenx novel fcrn-targeting therapies established ivig or plasmapheresis if clinical benefit cost-effectiveness doesn clearly beat older options adoption slows so needs robust phase iii data payer evidence reported revenue must show improved outcomes vs cost per patient to justify uptake.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003ePhysician choice high: IVIg\/plasma common\u003c\/li\u003e\u003cli\u003eCost gap: IVIg €5k–€15k\/yr vs biologic pricing\u003c\/li\u003e\u003cli\u003eData need: strong Phase III + real-world evidence\u003c\/li\u003e\u003cli\u003eInvestment: medical education, payer studies required\u003c\/li\u003e\n\u003c\/pphysicians\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers’ power slashes Vyvgart pricing—PBMs, HTAs, hospitals and patients squeeze margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (US PBMs\/insurers, hospitals) hold strong leverage—top 5 PBMs cover ~80% of US lives and routinely extract 30–40%+ rebates, cutting argenx’s net price for Vyvgart (2021) and pressuring margins; HTA bodies (NICE, IQWiG) impose price caps in Europe. Patient groups force ~$120–150m patient-support spend (2024), lowering realized price. Physicians can substitute IVIg (€5k–€15k\/yr) without clear superior outcomes, so argenx needs robust Phase III\/RWE to secure placement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eLeverage\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 5 PBMs\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eCover ~80% US lives; rebates 30–40%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHTA (NICE, IQWiG)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003ePrice caps, 12 major biologic appraisals (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/infusion networks\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eVolume discounts, extended terms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003ctd\u003ePatient-support $120–150m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysicians\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003ctd\u003eIVIg cost €5k–€15k\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003earGEN-X Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact arGEN‑X Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders, no mockups, fully formatted and ready to use.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the actual deliverable: a concise, professionally written evaluation of competitive rivalry, supplier and buyer power, threat of entry, and substitution—downloadable the moment you buy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747302289785,"sku":"argenx-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/argenx-five-forces-analysis.png?v=1772197349","url":"https:\/\/growthsharematrix.com\/products\/argenx-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}